Bannerbild German Brest Group

SASCIA (GBG 102) – successful start of the study!

12.11.2020

SASCIA (GBG 102) – successful start of the study!

First patient included.

The phase III postneoadjuvant study with the antibody-drug conjugate sacituzumab govitecan in women with early HER2-negative breast cancer and a high risk of relapse started successfully in November 2020.

We congratulate the gynecological clinic of the Caritasklinik St. Theresia, Saarbrücken for recruiting the first patient.

News

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd